Placebo Practice Trials: The Best Predictor of Adherence Readiness for HAART Among Drug Users?

REFERENCES

• Palella F, et al. Declining morbidity and mortality among patients with advanced HIV infection. New Engl J Med. 1998;338:853–860.
   PubMed Web of Science ®Google Scholar
• Cohn DC, et al. Continued benefit from highly active antiretroviral therapy: trends in AIDS-related opportunistic illnesses in a public health care system, 1990–2001. In: Program and abstracts of the XlVth International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Abstract ThOrC1443.
   Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Hecht FM, Charlebois E, Chesney M, Moss AR. Comparing objective methods of adherence assess-ment: electronic medication monitoring and unannounced pill count. AIDS Behav. 2001;5: 275–281.
   Google Scholar
• Arnsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic moni-toring. Clin Infect Dis. 200133: 1417–1423.
   Google Scholar
• Mathews WC, et al. Predictors, prevalence, and therapeu-tic effect of early adherence after starting or changing antiretroviral therapy. AIDS Patient Care STDS. 2002;16:157–172.
   PubMed Web of Science ®Google Scholar
• McNabb J, et al. Adherence to highly active antiretroviral therapy predicts outcome at an inner-city human immuno-deficiency virus clinic. Clin Infect Dis. 200133: 700–705.
   Google Scholar
• Wagner GJ, Ghosh-Dastidar B. Electronic monitoring: ad-herence assessment or intervention? HIV Clin Trials. 2002;3:45-51.
   Google Scholar
• Deeks S, Beatty G, Cohen PT, Grant R, Volberding P. Viral load and CD4 T cell changes in patients failing potent protease inhibitor therapy. In: Program and abstracts of the 5th Conference on Retroviruses and Opportunistic Infec-tions; February 1–5, 1998; Chicago, IL. Abstract 419.
   Google Scholar
• Moore R, Keruly J, Bartlett J, Chaisson R. Start HAART early (CD4>350 cells/mm3) or later? Evidence for greater effectiveness if started early. In: Program and abstracts of the 7th Conference on Retroviruses and Opportunistic In-fections; January 30-February 2, 2000; San Francisco, CA. Abstract 522.
   Google Scholar
• Little SJ, Routy JP, Daar ES, et al. Antiretroviral drug sus-ceptibility and response to initial therapy among recently HIV-infected subjects in North America. In: Program and abstracts of the 8th Conference on Retroviruses and Op-portunistic Infections; February 4–8, 2001; Chicago, IL. Abstract 755.
   Google Scholar
• Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resis-tant HIV. Nat Med. 2001;7: 1016–1020.
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents. Washington, DC; 2001.
   Google Scholar
• Santolaria-Fernandez FJ. Nutritional assessment of drug addicts. Drug Alcohol Depend. 1995;38:11–18.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Little SJ, Currier JS, et al. The value of patient-reported adherence to antiretroviral therapy in pre-dicting virologic and immunologic response. AIDS. 1999;13:1099–1107.
   PubMed Web of Science ®Google Scholar
• Mannheimer S, Hirsch W, El-Sadr W. The impact of the ALRTM alarm device on antiretroviral (AR) adherence among HIV-infected outpatients in Harlem. In: Program and ab-stracts of the 12th International AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 32325.
   Google Scholar
• Wenger N, Gifford A, Liu H, et al. Patient characteristics and attitudes associated with antiretroviral adherence. In: Program and abstracts of the 6th Conference on Antiretrovirals and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL.
   Google Scholar
• Chesney MA. Factors affecting adherence to antiretroviral therapy. Clin Infect Dis. 2000;30:S171–S176.
   PubMed Web of Science ®Google Scholar
• Weidle PJ, Ganea CE, Ernst J, McGowan J, Irwin KL, Holberg SD. Multiple reasons for nonadherence to antiretroviral medications in an inner-city minority popula-tion: need for a multifaceted approach to improve adher-ence. In: Program and abstracts of the 12th International AIDS Conference; June 28-July 3, 1998; Geneva, Switzer-land. Abstract 32360.
   Google Scholar
• Halkitis P, Remien RH, Parsons JT, Stirratt MJ. Factors related to protease inhibitor adherence among sexually active men-who-have-sex-with-men. In: Program and ab-stracts of the 12th International AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 60192.
   Google Scholar
• Celentano DD, Vlahov D, Cohn S, Shadle V, Obasanjo 0, Moore RD. Self-reported antiretroviral therapy in injection drug users. JAMA. 1998;280:544–547.
   PubMed Web of Science ®Google Scholar
• Strathdee SA, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547–549.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Hecht FM, Clague H, et al. Provider as-sessment of adherence to HIV antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;26:435–442.
   PubMed Web of Science ®Google Scholar
• Gross R, Bilker WB, Friedman HM, Coyne JC, Strom BL. Provider inaccuracy in assessing adherence and outcomes with newly initiated antiretroviral therapy. AIDS. 2002;16:1835–1836.
   PubMed Web of Science ®Google Scholar
• Prochaska JO. Assessing how people change. Cancer. 199167: 805–807.
   Google Scholar
• Willey C, Redding C, Stafford J, et al. Stages of change for adherence with medication regimens for chronic disease: development and validation of a measure. Clin Ther. 2000;22:858–871.
   PubMed Web of Science ®Google Scholar
• Konkle-Parker DJ. A motivational intervention to improve adherence to treatment of chronic disease. J Am Acad Nurse Pract. 2001;13:61–68.
   PubMedGoogle Scholar
• Dunbar-Jacob J. Contributions to patient adherence: Is it time to share the blame? Health Psychol. 1993;12(2):91–92.
   PubMed Web of Science ®Google Scholar
• Lerner BH, Gulick RM, Dubler NN. Rethinking nonadher-ence: historical perspectives on triple-drug therapy for HIV disease. Ann Intern Med. 1998;129:573–578.
   PubMed Web of Science ®Google Scholar
• Wagner GJ, Kanouse DE. Measuring the usual care control in adherence intervention trials. In: Program and abstracts of the XIV International AIDS Conference; July 7–12, 2002; Barcelona, Spain. Abstract WePeB5813.
   Google Scholar
• Bangsberg DR, Hecht FM, Charlebois E, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–366.
   PubMed Web of Science ®Google Scholar
• Wendel CS, Mohler MJ, Kroesen K, Ampel NM, Gifford AL, Coons J. Barriers to use of electronic adherence monitor-ing in an HIV clinic. Ann Pharmacother. 2001;35:1010–1015.
   PubMed Web of Science ®Google Scholar
• Spitzer RL, Williams JBW, Gibbon M. Structured Clinical Interview for DSM-IV. Washington, DC: American Psychiat-ric Press, 1995.
   Google Scholar
• McLellan AT, et al. The fifth edition of the Addiction Sever-ity Index. J Subst Abuse Treat 1992;9:199–213.
   PubMed Web of Science ®Google Scholar
• Remien RH, El-Bassel N, Caballo-Dieguez A, et al. Assess-ment scales for the SMART Couples Project. 2000.
   Google Scholar
• Stall R, Hoff C, Coates T, et al. Decisions to get HIV tested and to accept antiretroviral therapies among gay/bisexual men: implications for secondary prevention efforts. J Acquir Immune Defic Syndr Hum RetroviroL 1996;11:151–160.
   PubMedGoogle Scholar
• Chesney MA, Ickovics JR, Chambers DB, et al. Self-re-ported adherence to antiretroviral medications among par-ticipants in HIV clinical trials: the AACTG adherence instru-ments. AIDS Care. 2000;12:255–266.
   PubMed Web of Science ®Google Scholar
• Delis DC, Kramer JH, Kaplah E, et al. California Verbal Learning Test, Research Edition. Cleveland, OH: Psycho-logical Corp.; 1983.
   Google Scholar
• Army Individual Test Battery. Manual of Directions and Scoring. Washington, DC: War Department; 1944.
   Google Scholar
• Wechsler D. Wechsler Adult Intelligence Scale-Revised. New York: Psychological Corp.; 1981.
   Google Scholar
• Heaton RK, Grant I, Matthews CG. Comprehensive Norms for an Expanded Halstead-Re/tan Battery. Odessa, FL: Psychological Assessment Resources; 1992.
   Google Scholar
• Norman MA, Evans JD, Miller SW, Heaton RK. Demo-graphically corrected norms for the California Verbal Learning Test. J Clin Exp Neuropsychol. 2000;22:80–94.
   PubMed Web of Science ®Google Scholar
• Beck A, Beamsesderfer A. Assessment of depression: The depression inventory. In: Pichot P, ed. Psychological Mea-surements in Psychopharmacology. Basel: S. Karger; 1974:151–169.
   Google Scholar
• Wagner GJ, Iguchi M, Schneider S, Scott J, Anderson D. Placebo practice trials: a tool to assess and improve ad-herence readiness. HIV Clin Trials. 2002;3:475–481.
   PubMedGoogle Scholar
• Senecal C, Nouwen A, White D. Motivation and dietary self-care in adults with diabetes: Are self-efficacy and au-tonomous self-regulation complementary or competing constructs? Health Psychol. 2000;19: 452–457.
   PubMed Web of Science ®Google Scholar
• Thompson M, Gold M, Sathasivam K, et al. Adherence and relationship to antiretroviral efficacy in the H.E.A.R.T. (NZTA4006) study. Presented at: XIII International AIDS Conference; July 9–14, 2000; Durban, South Africa.
   Google Scholar
• Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dys-function and regimen complexity. Neurology. 2002;59:1944–1950.
   PubMed Web of Science ®Google Scholar
• Gifford AG, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in patients on multidrug antiretroviral regimens. J Acquir Im-mune Defic Syndr. 2000;23:386–395.
   PubMed Web of Science ®Google Scholar
• Catz SL, Kelly JA, Bogart LM, Benotsch EG, McAiliffe TL. Patterns, correlates and barriers to medication adherence among persons prescribed new treatments for HIV dis-ease. Health Psychol. 2000;19:124–133.
   PubMed Web of Science ®Google Scholar
• Duran S, Spire B, Raffi F, et al. Self-reported symptoms after initiation of a protease inhibitor in HIV-infected pa-tients and their impact on adherence to HAART. HIV Clin Trials. 2001;2:38–45.
   PubMedGoogle Scholar